NASDAQ:CNST

Constellation Pharmaceuticals Competitors

$22.50
-0.31 (-1.36 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.34
Now: $22.50
$23.17
50-Day Range
$22.81
MA: $27.32
$36.84
52-Week Range
$17.00
Now: $22.50
$50.90
Volume255,738 shs
Average Volume464,423 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.8

Competitors

Constellation Pharmaceuticals (NASDAQ:CNST) Vs. BHVN, HCM, EBS, ARNA, TPTX, and LEGN

Should you be buying CNST stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Constellation Pharmaceuticals, including Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), Arena Pharmaceuticals (ARNA), Turning Point Therapeutics (TPTX), and Legend Biotech (LEGN).

Biohaven Pharmaceutical (NYSE:BHVN) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Biohaven Pharmaceutical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Biohaven Pharmaceutical and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Earnings & Valuation

This table compares Biohaven Pharmaceutical and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.36
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40

Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Biohaven Pharmaceutical and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Constellation Pharmaceuticals02502.71

Biohaven Pharmaceutical currently has a consensus price target of $96.4545, suggesting a potential upside of 39.00%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Biohaven Pharmaceutical.

Summary

Constellation Pharmaceuticals beats Biohaven Pharmaceutical on 6 of the 11 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Hutchison China MediTech has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Hutchison China MediTech and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Constellation PharmaceuticalsN/A-28.88%-24.98%

Earnings & Valuation

This table compares Hutchison China MediTech and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40

Constellation Pharmaceuticals has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Constellation Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Hutchison China MediTech and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Constellation Pharmaceuticals02502.71

Hutchison China MediTech currently has a consensus price target of $40.00, suggesting a potential upside of 36.80%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Hutchison China MediTech.

Emergent BioSolutions (NYSE:EBS) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Emergent BioSolutions has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Institutional and Insider Ownership

80.2% of Emergent BioSolutions shares are owned by institutional investors. 14.1% of Emergent BioSolutions shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Emergent BioSolutions and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emergent BioSolutions12.50%26.68%12.70%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Earnings & Valuation

This table compares Emergent BioSolutions and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.11 billion3.73$54.50 million$2.9126.58
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40

Emergent BioSolutions has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Emergent BioSolutions and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emergent BioSolutions02502.71
Constellation Pharmaceuticals02502.71

Emergent BioSolutions currently has a consensus price target of $109.8333, suggesting a potential upside of 42.00%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Emergent BioSolutions.

Summary

Emergent BioSolutions beats Constellation Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Arena Pharmaceuticals (NASDAQ:ARNA) and Constellation Pharmaceuticals (NASDAQ:CNST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current ratings for Arena Pharmaceuticals and Constellation Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arena Pharmaceuticals001503.00
Constellation Pharmaceuticals02502.71

Arena Pharmaceuticals currently has a consensus price target of $91.80, suggesting a potential upside of 38.48%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Given Constellation Pharmaceuticals' higher probable upside, analysts plainly believe Constellation Pharmaceuticals is more favorable than Arena Pharmaceuticals.

Volatility & Risk

Arena Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Profitability

This table compares Arena Pharmaceuticals and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arena PharmaceuticalsN/A-33.17%-30.41%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Institutional and Insider Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Arena Pharmaceuticals and Constellation Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arena Pharmaceuticals$806.43 million4.96$397.55 million$7.698.62
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40

Arena Pharmaceuticals has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Constellation Pharmaceuticals and Turning Point Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Constellation Pharmaceuticals02502.71
Turning Point Therapeutics00703.00

Constellation Pharmaceuticals currently has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Turning Point Therapeutics has a consensus price target of $153.7143, suggesting a potential upside of 94.70%. Given Constellation Pharmaceuticals' higher probable upside, equities research analysts plainly believe Constellation Pharmaceuticals is more favorable than Turning Point Therapeutics.

Risk and Volatility

Constellation Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Constellation Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Constellation PharmaceuticalsN/A-28.88%-24.98%
Turning Point TherapeuticsN/A-23.81%-23.08%

Institutional & Insider Ownership

81.3% of Turning Point Therapeutics shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Turning Point Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-26.40

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Constellation Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Turning Point Therapeutics beats Constellation Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Constellation Pharmaceuticals and Legend Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Constellation Pharmaceuticals02502.71
Legend Biotech00303.00

Constellation Pharmaceuticals currently has a consensus price target of $45.2857, suggesting a potential upside of 101.27%. Legend Biotech has a consensus price target of $50.6667, suggesting a potential upside of 78.09%. Given Constellation Pharmaceuticals' higher probable upside, equities research analysts plainly believe Constellation Pharmaceuticals is more favorable than Legend Biotech.

Profitability

This table compares Constellation Pharmaceuticals and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Constellation PharmaceuticalsN/A-28.88%-24.98%
Legend Biotech-543.73%-205.60%-43.03%

Institutional & Insider Ownership

18.9% of Legend Biotech shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Legend Biotech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.40
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Constellation Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech.

Summary

Constellation Pharmaceuticals beats Legend Biotech on 7 of the 10 factors compared between the two stocks.


Constellation Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.